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Abstract
Auditory and Vestibular medicine is becoming more accepted as a specialty of its own, Medical
NeurOtology. Recent advances in the field have been instrumental in the understanding of the
scientific foundations, pathophysiology, clinical approach and management of patients with
hearing and vestibular disorders. This paper will review these advances.
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Introduction
Auditory and vestibular medicine, also known as Medical NeurOtology, is an evolving
medical specialty that focuses on disorders and diseases of the inner ear and related central
nervous system structures. Auditory and vestibular medicine physicians should be well
versed in general medicine, neurology and otology. Additional knowledge in neuroscience,
physics, engineering and acoustics is also important. At the moment, the specialty is well
positioned in Europe as compared to other parts of the world. Hearing loss is the most
common handicap in the world. In the industrialized world, the incidence of hearing loss is
25% in people under age 25 and reaches 40% in persons over age 40. Congenital and
prelingual deafness occurs in 1/1000 children. Tinnitus is reported by 25% of the population.
The incidence of dizziness, vertigo and/or imbalance is 5-10% and reaches 40% after age
40. The incidence of falling is 25% in subjects over 65. Falling can be a direct consequence
of vestibular diseases, especially in patients with multiple sensory deficits. Migraine is a
more prevalent disorder (10%) than Meniere’s disease (< 1%). However, vertigo and motion
sickness are present in 30% and 50% respectively of migraine patients, which makes it
difficult sometimes to distinguish migraine-associated dizziness from primary inner ear
diseases.
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Advances in the understanding of inner ear molecular biology, genetics, regenerative
medicine, ion homeostasis, electrophysiology and diagnostic modalities have increased our
abilities to further understand inner ear disease and develop new management strategies.
Central to these advances is the departure from viewing the inner ear as a fluid based system
to the more physiologically based view as an ionic transport system. Also critical are the
continual advances in understanding the processes underlying auditory and vestibular
rehabilitation and compensation following diseases affecting these systems.
The work up of patients with inner ear disorders and diseases requires time and resources
that are gradually diminishing given the current medical economics worldwide.
Consequently, the demand on Auditory and Vestibular physicians to manage these patients
in a cost effective manner has increased over the last decade. This review will discuss recent
advances in the field with emphasis on recent basic science findings and their potential
clinical applications.
Ion Homeostasis in the Ear
The inner ear is essentially an organ of ion homeostasis and can function properly only if its
ion balances are tightly controlled. Any disruption of normal ion transport will significantly
compromise hearing and balance. These ion-regulated functions include endolymph and
perilymph production, hair cell transduction, and nerve conduction. There are dozens of ion
transport channels and transporters in the inner ear, and undoubtedly more will be
characterized1. The majority move K+, Na+, Ca++, Cl−, H+, −OH, HCO3−, as well as other
ions2–4. However, there are other factors that control fluid and ion movements, including
atrial natriuretic peptides, aquaporins, and transient receptor potential vallinoid ion
channels5–8. Inner ear ion transporters and channels are controlled by numerous natural
hormones, such as aldosterone (mineralocorticoid), cortisol or hydrocortisone
(glucocorticoid), diuretics and anti-diuretics (vasopressin), thyroid hormone, and estrogen,
as well as nucleotides and other enzymes9–12. Thus, abnormal levels of these hormones can
impact inner ear physiology. Also, many of these ion transport channels and transporters are
absent or defective in various genetic disorders, making an understanding of their functions
critical for the evaluation of congenital hearing disorders4;13–15.
Perhaps the best studied ion homeostatic mechanism is that of K+ transport, which is tied
closely to that of Na+. Endolymph requires a higher K+ content than perilymph (high Na+)
to maintain the endocochlear potential and allow hair cell depolarization. Therefore, many
transporters and channels are in place to keep K+ moving into the endolymph, through the
hair cell into the perilymph during transduction, and cycling back to the endolymph.
Because the composition of endolymph is similar to intracellular fluid, a hair cell could not
function if it was surrounded by endolymph (no potential difference). This dilemma is
solved by surrounding the stereocilia with endolymph to provide the necessary high K+, but
surrounding the cell body (beneath the reticular lamina) with perilymph, which is similar to
extracellular fluid. Once K+ exits the hair cell and enters the extracellular (perilymph) space,
a series of gap junctions (connexins) move K+ through the supporting cells to the spiral
ligament fibrocytes, and up to the stria vascularis for its transport back into the endolymph.
There also appear to be other medial or lateral routes taken by K+ to eventually reach the
stria16;17. Once K+ reaches the stria vascularis, it is moved into the endolymph through a
series of transporters and channels, including several K+ channels, Na+,K+-ATPase, Na+-
K+-2Cl−, and possibly others. Most of these K+ transport mechanisms are under the control
of the mineralocorticoid aldosterone and the antidiuretic vasopressin.
There are a number of disorders that compromise this movement of K+ and cause hearing
loss. Congenital genetic defects occur in the gap junction connexins, the various K+
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channels, or other ion channels that are need to work in tandem with the K+ channels4;18–22.
Furthermore, disruption of the endothelial cell tight junctions in the stria due to connexin
defects also can lead to hearing loss by eliminating the endocochlear potential23;24. It has
been demonstrated that stria intermediate cells, basal cells and fibrocytes are all
interconnected by gap junctions, with the syncitium possibly including endothelial cells, as
well24;25. Thus, K+ cycling and transport can be compromised by gene defects or disease
processes that affect any of these cellular components. It also has been reported that loss of
aldosterone with aging may lead to presbycusis, possibly by interfering with this process26.
The impact of glucocorticoids on this mineralocorticoid function also has been shown
experimentally27–29 suggesting the K+ transport system may respond to therapeutic anti-
inflammatory steroids, such as prednisone and dexamethasone.
Vestibular functions also are rigidly tied to inner ear ion homeostasis and the same ion
channels described above appear throughout the vestibular sensory epithelia. The dark cells
surrounding these epithelia, and their adjoining duct cells, house numerous ion channels that
maintain similar ion homeostatic processes2;30–32. Like in the cochlea, ongoing studies are
beginning to clarify these channels and what natural or therapeutic steroids control their
functions.
Vestibular Compensation
‘Vestibular compensation’ (VC) is a general term for the behavioral recovery of oculomotor
and postural control that occurs after damage to the vestibular system. In its most widely-
studied form, VC refers to the recovery after a permanent loss or deafferentation of the
semicircular canal and macular receptors of one inner ear (e.g. after unilateral
labyrinthectomy, or vestibular neurectomy). Because the vestibular loss is permanent, it is
accepted that VC must involve extensive synaptic and neuronal plasticity in the brainstem
vestibular nuclei, cerebellum, and related brain areas33–35. Similar forms of VC, no doubt
with common brain plasticity mechanisms, also take place after the partial or incomplete
loss of peripheral vestibular inputs. In the clinical context peripheral vestibular damage may
often occur gradually over a prolonged time, in which case VC is also an ongoing process
which continuously attempts to normalize oculomotor and postural motor control.
Mechanisms of vestibular compensation
Experimental studies have shown that unilateral vestibular deafferentation (UVD) has
profound effects on the activity of vestibular nucleus (VN) neurons. Of the four main
vestibular nuclei in the brainstem, the most extensively studied is the medial vestibular
nucleus (MVN). Immediately after UVD the normally high resting discharge of the majority
of MVN neurons on the ipsi-lesional side is virtually abolished, while the activity of contra-
lesional MVN neurons is either normal or increased. The silencing of ipsi-lesional MVN
neurons is due not only to the loss of primary afferent excitation from the lesioned labyrinth,
but also to an increased commissural inhibition from the contra-lesional side. The
subsequent amelioration of the initially severe symptoms (ocular nystagmus, head and body
roll and yaw tilt, postural instability) is broadly correlated with a recovery of resting activity
in ipsi-lesional MVN neurons to near-normal levels, and a “re-balancing” of the
commissural inhibitory system. Much research has therefore focused on understanding the
causes of the initial silencing of the ipsi-lesional MVN cells after UVD, and the mechanisms
that may bring about the recovery of their resting activity early in VC.
On the basis of experimental evidence, at least four candidate synergistic mechanisms have
been proposed which may be important in the early stages of VC34.
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1. Changes in the responsiveness of vestibular nucleus neurons to inhibitory
neurotransmitters GABA and glycine. Studies of in vitro slice preparations of the
brainstem have revealed many of the electrophysiological characteristics of MVN
neurons and the actions of various neurotransmitters that influence vestibular
function. Comparison of the responsiveness of MVN neurons to the inhibitory
neurotransmitters GABA and glycine, in slices from normal animals and animals
that had compensated for various times after UVD, showed that the sensitivity of
the ipsi-lesional MVN neurons to these inhibitory transmitters is significantly
down-regulated. This is appropriate to counteract the enhanced commissural
inhibition to which the ipsi-lesional MVN cells are subjected after UVD, and so
may help to restore their resting discharge early in VC.
2. Changes in the electrophysiological excitability of vestibular nucleus neurons after
deafferentation. In parallel, ipsi-lesional MVN cells also up-regulate their intrinsic
electrophysiological excitability. This involves changes in their input resistance and
resting membrane potentials, and a potentiation of their responsiveness to synaptic
inputs through the up-regulation of appropriate ion channels. In particular there is
an increase in the number of cells that show low-threshold calcium spikes (LTS),
which may significantly increase their responsiveness to their remaining non-
vestibular synaptic inputs. In the longer term these changes in intrinsic properties of
the ipsi-lesional MVN neurons persist, and additional changes also occur in the
properties of contra-lesional MVN neurons. The excitability, neurotransmitter
sensitivity and signal-processing characteristics of the vestibular neurons are
therefore permanently modified over the course of VC.
3. Adaptive changes in synaptic connectivity in the vestibular reflex networks. In the
course of VC over several weeks, the synaptic connectivity of excitatory and
inhibitory pathways in the brainstem vestibular networks also undergoes gradual,
activity-dependent re-organisation. Thus MVN neurons that are deprived of their
original synaptic inputs after deafferentation, become responsive to excitatory
inputs from other, intact afferents. This substitution of inputs through synaptic re-
organisation is similar to that in other sensory systems. For example, the area of the
somatosensory cortex concerned with a particular body part gradually becomes
responsive to inputs from adjacent regions if its normal input is deafferented. In the
vestibular nuclei, such ‘re-wiring’ of synaptic connectivity has the benefit that the
deafferented MVN neurons receive substitute excitatory inputs which may restore
and maintain their activity. However, the re-wired connections may now generate
quite inappropriate vestibular reflexes. For example, MVN neurons previously
concerned with horizontal canal afferents may now receive synaptic excitation from
macular afferents and generate horizontal eye movements in response to vertical
head movements. An important part of the overall behavioural recovery in VC may
therefore involve the suppression of such inappropriate reflexes, for example by
alternative strategies for gaze stabilization.
4. Post-lesional changes in the control of vestibular nucleus neurons by the
cerebellum. While the cerebellum, and in particular the flocculus, has long been
known to be important in calibrating the gaze-stabilizing function of the vestibulo-
ocular reflex (VOR), its role in VC has been unclear. Ocular nystagmus in
flocculectomised animals eventually disappears completely, suggesting the
flocculus is not essential for VC. Other processes, such as those discussed above,
also may achieve compensation, but over a longer time period. However for the
normal development of VC, and the relatively rapid subsidence of nystagmus
within a few days, the flocculus appears to play an important, but as yet unclear,
role.
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Interactions between stress and brain plasticity during VC
The development of vestibular compensation after UL is significantly affected by stress, as
well as conditions such as anxiety and depression, where the normal function of the
hypothalamo-pituitary-adrenal (HPA) stress axis is altered34;36. Glucocorticoids (GCs)
released by the adrenal cortex in response to stress have important modulatory effects on
neuronal and synaptic function in the brain. GCs may act directly on membrane ion channels
and neurotransmitter receptors, or they may alter gene expression in neurons through
specific intracellular receptors (glucocorticoid receptors, GRs or mineralocorticoid
receptors, MR); and they may be rapidly converted to active neurosteroids.
A number of studies suggest that glucocorticoids and neurosteroids modulate vestibular
system function and compensation37–41. Anxiety and stress in patients with vertigo
significantly delays the recovery from vestibular symptoms. Conversely, treatment of
patients with the methylprednisolone has been reported to improve VC. In animal models
both the behavioral recovery and the changes in electrophysiological properties of MVN
neurons, are facilitated by dexamethasone and inhibited by the GR antagonist RU3848642.
However, a critical level of stress activation appears to be required, since additional stress in
the form of restraint applied to compensating animals after UVD retards VC. Such
interactions may have important implications for patients with balance disorders. Effective
vestibular rehabilitation after vestibular loss is achieved by exercise and training which
involves stimulation of the visual and somatosensory systems, presumably allowing activity-
driven sensory substitution in the central vestibular pathways43;44;44. It may also be relevant
that such exercises also stimulate a moderate stress response that may facilitate brain
plasticity. Slow or incomplete compensation in some patients could involve altered
responses to stress, as in depression or anxiety, though this remains to be established.
To what extent can remaining sensory information and/or sensory biofeedback (BF)
compensate for loss of vestibular information in controlling postural equilibrium? The
primary role of the vestibulospinal system is as a vertical reference for control of the trunk
in space, with increasing importance as the surface becomes increasingly unstable. Our
studies with patients with bilateral loss of vestibular function show that vision or light touch
from a fingertip can substitute as a reference for earth vertical to decrease variability of
trunk sway when standing on an unstable surface. However, some patients with bilateral loss
compensate better than others, and those with more complete loss of bilateral vestibular
function compensate better than those with measurable vestibulo-ocular reflexes. In contrast,
patients with unilateral vestibular loss (UVL) who reweight sensory dependence to rely on
their remaining unilateral vestibular function show better functional performance than those
who do not increase vestibular weighting on an unstable surface. Light touch of <100 grams
or auditory biofeedback can be added as a vestibular vertical reference to stabilize trunk
sway during stance. Postural ataxia during tandem gait in patients with UVL is also
significantly improved with vibrotactile BF to the trunk, beyond improvements due to
practice. Vestibular rehabilitation should focus on decreasing hypermetria, decreasing an
overdependence on surface somatosensory inputs, increasing use of any remaining
vestibular function, substituting or adding alternative sensory feedback related to trunk
sway, and practicing challenging balance tasks on unstable surfaces. Irrespective of which
format or setting of vestibular rehabilitation, it must stimulate and gradually challenge the
vestibulocoular, vestibulospinal and their visual interaction to initiate and maintain VC44.
Regenerative medicine and the inner ear
The application of regenerative medicine45 , molecular genetics46, and the use of embryonic
stem cells to create inner ear hair cells has been rapidly advancing since it was shown that
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birds have the ability to rebuild damaged auditory hair cells47. Several studies are currently
exploring different cell lines, genetic vectors and autologous cells to circumvent rejection
and to increase survival and functionality of regenerated cells48–51. Detailed discussion of
this subject is beyond the scope of this review. Suffice to say that it is of critical importance
to the future of Auditory and Vestibular Medicine as it will impact the management of most
if not all types of hearing and vestibular diseases.
Clinical Approach to patients with Auditory and Vestibular Disorders
In medicine, history and physical examination are the corner stones of optimal medical care.
This is particularly true in Auditory and Vestibular Medicine52. The history of hearing loss
in children should include pregnancy and delivery problems and family history of hearing
loss. In adults, history of ototoxic medications, noise exposure, ear disease or surgery, and
allergies should be included. Fluctuating hearing, aural fullness or pressure and tinnitus
should be documented. In eliciting the history of vertigo, dizziness or imbalance, patients
should be guided when necessary to classify “dizziness” into two main categories; vertigo
and non-vertigo. This dichotomy is helpful as rotational vertigo is often due to inner ear
disease whereas non-vertigo symptoms may be due to CNS, cardiovascular or systemic
diseases. Incoordination and inability to walk during episodes can be due to cerebellar
diseases, especially in the elderly population. Continuous dizziness, motion sensitivity, drop
attacks and falls should be evaluated. History of migraine, head trauma and prior viral
illness is important. The history should include careful review of systems and screening for
anxiety/depression. History of prescription medicines, over-the-counter medications, herbal
medicines and recreational drugs (including smoking and alcohol) is helpful to identify
“pharmacologically” induced dizziness/lightheadedness.
Traditional medical, neurological and ENT examination of hearing loss and vertigo are
important. The ear exam should be done with a microscope when possible, especially in
patients with prior ear surgery or recent ear trauma. Hearing can be screened using tuning
forks. Vertigo patients in particular require an additional/complementary “Vestibular
Examination” which focuses on neck and eye movements, and vestibular and postural
responses. The neck is examined for range of motion, stiffness and provoked symptoms. Eye
movements are examined in all cardinal directions in searching for gaze, spontaneous, post
head shake and positional nystagmus. Central nystagmus is purely horizontal or vertical and
is seen with visual fixation. Peripheral nystagmus is usually rotatory and is present with
removing optic fixation (e.g. under closed eyelids, use of Frenzel’s glasses or video
monitoring). A fairly reliable clinical impression of the horizontal and vertical vestibular
ocular reflex (VOR) can be ascertained by observing (or video taping) the presence,
‘intensity” and symmetry of per-rotatory nystagmus during and after active head movements
by the examining physician (or by rotating the patient’s exam chair manually). With time
and experience, unilateral and bilateral reduced vestibular responses can be determined
during this test. Nystagmus and vertigo symptoms during the Dix-Hallpike exam are typical
findings in benign positional vertigo (BPPV). Focused neurological examination of the
cranial nerves, motor and sensory modalities, gait and stance are important at the initial visit.
Cerebellar tests, especially failure of fixation suppression, are important to check the
vestibulo-cerebellum. Failure of fixation suppression can be tested in the office by asking
patients to stretch their arms and look at their thumbs while being passively rotated (manual
rotation of examination chair). A visible nystagmus (left or right) indicates failure of
fixation suppression that is always central in origin. Gait is evaluated by asking patients to
stand up and walk several steps forward and backward. The examining physician can
qualitatively document ability to stand up without assistance, gait speed and stride length.
The use of a high compliant foam pad to examine posture control is very helpful in
“stressing” the system to evaluate postural sway, limits of stability and strategies (hip vs.
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ankle sway). The examining physician should attempt to evaluate these parameters, as they
are very helpful in addressing pathophysiology of falling and in tailoring appropriate
vestibular rehabilitation programs. This is very critical in elderly patients who are evaluated
for the primary complaint of falling. If the above exams are normal and the history is not
specific for a primary ear or brain disease, hyperventilation for 2 minutes is helpful in
identifying patients with “hyperventilation syndrome”, particularly if it reproduces their own
symptoms.
DIAGNOSTIC TESTS
Additional tests that are helpful in diagnosing ear problems include audiometry, vestibular
tests, blood tests, CT and MRI. However, these tests need to be tailored according to the
history and physical findings. Basic and advanced audiometry, especially if hearing loss
and/or tinnitus are present, help narrow the diagnosis and tailor appropriate treatments.
Vestibular testing with standard Electronystagmography (ENG or VNG) is helpful to
confirm unilateral or bilateral vestibular loss and the presence of spontaneous and or
positional nystagmus. It is seldom sensitive to abnormal eye movements which are best
observed or video recorded during the physical examination. Vestibular evoked myogenic
potentials (VEMP) are useful in evaluating the otolith organs. Advanced vestibular tests
(chair and posturography) are helpful in selected patients who continue to have vestibular
symptoms (i.e. incomplete central compensation) despite adequate treatment. It is not cost
effective or medically indicated to obtain chair and posturography at the initial work up of
the dizzy patient. Auditory brainstem response (ABR), Electro-Cochleography (ECoG),
Otoacoustic emission (OAE) are helpful to confirm an inner ear diseases, to rule out central
disease and to tailor and monitor treatments.
Screening blood tests for thyroid function, diabetes, lipids and autoimmune diseases are
helpful in selected patients. Immune mediated inner ear tests which include ANA, ESR, RF
and 68 KD western blot, are expensive and their yield is low.
Brain MRI scans are frequently “normal” in vestibular patients under the age of 50. Acoustic
tumors and brain lesions that do not have clinical symptoms or signs on detailed vestibular
and neurotological examinations are rare. The probability of an acoustic tumor in patients
with unilateral hearing loss or tinnitus is less than ½ %. It is appropriate, therefore, to
increase our threshold in ordering MRI studies in this patient population unless there are
clear clinical signs and symptoms of brain disease. High-resolution CT scans are helpful
when inner ear bony anomalies are suspected; for example large vestibular aqueduct or
dehiscence of the superior semicircular canal.
Common disorders of Auditory and Vestibular Disorders
In general, the most common causes of hearing loss are presbyacusis and noise (industrial
and recreational) induced hearing loss in adults and non syndromic hearing loss in children.
Hearing loss due to chronic ear disease is declining because of the advent of antibiotics and
allergy management. Sudden hearing loss53;54, auditory neuropathy55 and other types of
central hearing loss are rare. The most common causes of peripheral vertigo and imbalance
are vestibular neuritis, BPPV, Meniere’s disease, and presbystasis. The most common cause
of “central” dizziness is vestibular Migraine56–58 and to a lesser extent hyperventilation
induced dizziness. Other central causes include demyelination, acoustic tumors or cerebellar
lesions. Central dizziness due to vertebrobasilar insufficiency (VBI) or vascular etiology in
general, is uncommon. Isolated vertigo or dizziness is unlikely due to VBI unless other
brainstem symptoms/signs and vascular risk factors exist. Disequilibrium of aging and gait
disorders leading to falling are prevalent in the elderly population and are usually due to
multi-sensory deficits involving vision, proprioception, hearing and vestibular functions.
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Management of common Auditory and Vestibular disorders
Management should always be directed to underlying pathophysiology when possible. Age
related hearing loss and noise induced hearing loss are usually treated with hearing aids,
assistive listening devices and protection from noise and ototoxic medications when
possible. Sudden hearing loss is commonly treated with oral and/or intratympanic steroids59.
The yield is not particularly high but it continues to be the standard of practice in many
countries. Congenital and hereditary hearing loss is commonly treated with hearing aids,
cochlear implants or both. Auditory and speech rehabilitation is of critical importance in
these cases60. Gene therapy of the human inner ear remains a future possibility given the
existing knowledge and experience in animal studies49;61. The current treatments for
tinnitus and auditory neuropathy remain empirical and are based on a mutimodalities
approach.
Acute dizziness and vertigo is usually managed as an out-patient with vestibular
suppressants (IM, IV or sublingual) and anti-emetic medications. Steroids can be used in
selected patients. Vestibular suppressants should be used for a few days at most because
they delay the brain’s natural compensatory mechanism for peripheral vertigo. Recurrent
BPPV is best treated with canalith repositioning maneuvers62.
Acute vestibular neuritis is treated symptomatically and patients should start home or clinic
based vestibular rehabilitation44 as soon as possible to boost vestibular compensation. In
general most patients experience significant resolution of symptoms with in 6–8 weeks.
Meniere’s disease or atypical BPPV should be considered in patients who continue to have
imbalance and motion intolerance symptoms despite adequate trials of vestibular
rehabilitation.
Meniere’s disease first line of treatment is low salt and diuretics63. Vestibular suppressants
can be used to abort exacerbations of vertigo. Intra-tympanic perfusion64 of steroids or
gentamicin is very effective in Meniere’s disease. Steroids are used in early stages of the
disease to stabilize hearing and control vertigo and gentamicin in late stages to control
vertigo and Tumarkin drop attacks. It is important to provide early and aggressive treatment
to hopefully bring hearing (mostly speech discrimination) to an “aidable” level, keeping in
mind that these patients have a 25 % chance of developing Meniere’s in the other ear.
Autoimmune inner ear disease [AIED]65;66 is commonly seen in middle age females. The
typical presentation is bilateral, or unilateral, rapidly progressive sensorineural hearing loss
with or without vertigo. It is usually associated with other autoimmune diseases, but it can
be an isolated ear disease. Blood tests are available but they are not highly sensitive or
specific. The history, audiometric and vestibular evaluations, absence of other diseases and
positive response to steroids are the hallmarks of this disease. Generally, 1mg/kg/day (single
dose, max 60mg/day) regimen is used for one month after which steroids are tapered slowly
(with good response) or rapidly (with no response). Intratympanic steroids perfusion can be
also used in these patients. Other immunosuppressive medications (e.g. Methotrexate) can
be used as primary treatment or as steroid sparing medication67.
Vestibular Migraine56;57 is treated with multimodal approach utilizing avoidance of triggers,
prophylactic and abortive medications, and stress management. There are many options of
medications such as triptans, anti anxiety, beta blockers, calcium channel blockers,
antiepileptic medications and antidepressants. Sometimes it takes a trial and error approach
to find out most effective approach. Critical to the management of vestibular migraine is not
to use narcotics to avoid dependence and rebound effects.
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Dysequilibrium of aging (“presbystasis”), gait disorders and consequent falling should be
carefully evaluated for both intrinsic and extrinsic factors. Intrinsic causes include
degenerative and neurological diseases especially multi-sensory deficits of vision, hearing
and vestibular functions. Age related changes in gait and balance are subtle and may go
unnoticed by patients and physicians. Appropriate sensory-motor integration of the three
cardinal sensory modalities; vision, proprioception and vestibular, is critical for postural
stability. The vestibular input is the least redundant and most conserved with aging.
Therefore, the brain predominantly “looks” for the vestibular system for postural stability.
Consequences of even mild forms of inner ear disease in the elderly are much more evident
and serious as they can lead to falling. Early interventions to control inner ear disease and to
start home based vestibular rehabilitation44 are very critical in this population. Vestibular
suppressants must be used sparingly. Most vestibular patients can effectively do home
vestibular rehabilitation on their own. This is both convenient and cost effective especially
in today’s medical economics. In few selcted patients, occupational and physical therapy are
helpful in addressing home safety, mechnical neck and postural problems that can impede
vestibular rehabilitation, and to insure compliance with therapy.
Hyperventilation syndrome patients are treated with explanation of the diseases process and
use of re-breathing exercises. Otherwise, additional cognitive therapy, stress management
and medications are required.
Summary
Recent advances in the understanding of the auditory and vestibular systems are making it
possible to more effectively manage their disorders. Thus, our insight into inner ear disease
has significantly advanced with regard to the underlying cellular and molecular control of
the fluid homeostasis in the ear, plasticity and compensatory mechanisms within the central
vestibular pathways, and diagnostic protocols that isolate specific vestibular pathologies.
This has ultimately led to better management of hearing and vestibular disorders because of
our ability to target therapies to deal with disease, as well as symptoms. In view of the rapid
research progress being made in all fields of otology, we anticipate many of these findings
will dramatically improve our ability to effectively control, and reverse, the many ear
disorders plaguing our society.
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